Madrigal: Identifying, Managing and Treating Patients with NASH and Significant Fibrosis – Current Practice and Future Perspectives - ILC 2022
View
Metabolism, Alcohol & Toxicity
5
Madrigal: Identifying, Managing and Treating Patients with NASH and Significant Fibrosis – Current Practice and Future Perspectives - ILC 2022
View
Metabolism, Alcohol & Toxicity
5
Madrigal: Identifying, Managing and Treating Patients with NASH and Significant Fibrosis – Current Practice and Future Perspectives - ILC 2022
View
Liver Tumours
5
Boston Scientific: Radioembolisation in the BCLC and beyond: An MDT approach - Liver Cancer Summit 2022
View
Liver Tumours
5
Boston Scientific: Radioembolisation in the BCLC and beyond: An MDT approach - Liver Cancer Summit 2022
View
Liver Tumours
5
Boston Scientific: Radioembolisation in the BCLC and beyond: An MDT approach - Liver Cancer Summit 2022
View
Liver Tumours
5
Boston Scientific: Radioembolisation in the BCLC and beyond: An MDT approach - Liver Cancer Summit 2022
View
Liver Tumours
5
Boston Scientific: Radioembolisation in the BCLC and beyond: An MDT approach - Liver Cancer Summit 2022
View
Metabolism, Alcohol & Toxicity
2
Madrigal: Phase 3 Development of Resmetirom, a liver directed thyroid hormone receptor (THR)-β agonist for the treatment of patients with NASH and significant liver fibrosis - ILC 2021
View
Metabolism, Alcohol & Toxicity
2
Madrigal: Phase 3 Development of Resmetirom, a liver directed thyroid hormone receptor (THR)-β agonist for the treatment of patients with NASH and significant liver fibrosis - ILC 2021
View
Liver Tumours
6
Boston Scientific: SIRT: The versatility of current HCC treatment & the opportunities for the future - Digital Liver Cancer Summit 2021
View
Liver Tumours
6
Boston Scientific: SIRT: The versatility of current HCC treatment & the opportunities for the future - Digital Liver Cancer Summit 2021
